BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chebli JMF, Queiroz NSF, Damião AOMC, Chebli LA, Costa MHM, Parra RS. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician. World J Gastroenterol 2021; 27(11): 1022-1042 [PMID: 33776370 DOI: 10.3748/wjg.v27.i11.1022] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Alrashed F, Alasfour H, Shehab M. Impact of biologics and small molecules for inflammatory bowel disease on COVID ‐19‐related hospitalization and mortality: A systematic review and meta‐analysis. JGH Open. [DOI: 10.1002/jgh3.12728] [Reference Citation Analysis]
2 Langley BO, Guedry SE, Goldenberg JZ, Hanes DA, Beardsley JA, Ryan JJ. Inflammatory Bowel Disease and Neutrophil-Lymphocyte Ratio: A Systematic Scoping Review. J Clin Med 2021;10:4219. [PMID: 34575330 DOI: 10.3390/jcm10184219] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Dvornikova KA, Bystrova EY, Churilov LP, Lerner A. Pathogenesis of the inflammatory bowel disease in context of SARS-COV-2 infection. Mol Biol Rep 2021;48:5745-58. [PMID: 34296352 DOI: 10.1007/s11033-021-06565-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Melgaço FG, Azamor T, Villar LM, Ano Bom APD, Melgaço JG. Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn's Disease after COVID-19 Vaccination: A Twin Case. Viruses 2021;13:2143. [PMID: 34834950 DOI: 10.3390/v13112143] [Reference Citation Analysis]
5 Stallmach A, Reuken PA, Grunert P, Teich N. [Inflammatory bowel disease during the COVID-19 pandemic: manifestations and management]. Z Gastroenterol 2022. [PMID: 35148564 DOI: 10.1055/a-1744-6697] [Reference Citation Analysis]
6 M’koma AE. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina 2022;58:567. [DOI: 10.3390/medicina58050567] [Reference Citation Analysis]
7 Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 2022. [PMID: 34988877 DOI: 10.1007/s12325-021-01990-6] [Reference Citation Analysis]
8 Chen F, Dai Z, Huang C, Chen H, Wang X, Li X. Gastrointestinal Disease and COVID-19: A Review of Current Evidence. Dig Dis 2021. [PMID: 34510032 DOI: 10.1159/000519412] [Reference Citation Analysis]